Helium-3 & cryogen supply

The warhead byproduct quantum can't ship without

Helium-3 is not produced; it accumulates. Essentially all Western supply is collected when the NNSA services aging tritium reservoirs in US nuclear weapons, then rationed through the DOE Isotope Program — Russia is the only other source at scale. The upstream owners of this choke are two governments, neither of which responds to price. Downstream, every dilution refrigerator — the only commercially proven way to hold superconducting and spin qubits near 10 mK — carries a He-3 charge that Science pegs at up to a quarter of the >$600,000 cost of a fridge, against a US stockpile of roughly 90,000 liters. Industry estimates put terrestrial output at ~22,000–30,000 liters a year versus 40,000–60,000 liters of demand from quantum, neutron detection, medical imaging and fusion R&D (PostQuantum's cryogenic infrastructure guide). The commercial pinch sits with private Bluefors, the dominant fridge maker, which just made the largest known commercial He-3 commitment in history: up to 10,000 liters a year of lunar He-3 from Interlune, 2028–2037. When the market leader pre-buys a decade of moon-mined gas, it is telling you what it thinks of terrestrial supply.

US-listed exposure is more direct than the market assumes — at the very top. Linde (LIN) is the DOE Isotope Program's commercial distribution channel for US He-3 through its former Spectra Gases specialty-gas business, and owns the only US NRC-licensed facility for stripping tritium from raw He-3 (GAO-11-472) — arguably the most direct He-3 touch of any exchange-listed name, however immaterial to group revenue. Air Liquide (AIQUY) also sells He-3: its Advanced Technologies arm is a He-3 gas supplier and owns fridge maker Cryoconcept. The only US-listed dilution-fridge maker is FormFactor (HPD). Both gas majors, plus Air Products, move bulk He-4 — the workhorse cryogen for precooling and for ~4 K photonic machines; Linde is building one of the largest quantum-dedicated cryoplants ever for PsiQuantum in Brisbane. ASP Isotopes, after closing Renergen in January 2026, becomes a rare independent liquid-helium producer.

Breaking the choke takes one of three things. More tritium irradiation — a deterrence decision, not a market one; the byproduct supply curve is vertical in both directions. Lunar extraction — in May 2025 DOE signed its first-ever purchase of a non-terrestrial resource (3 liters from Interlune, delivery by April 2029): trivial volume, enormous legitimacy, execution entirely unproven. Or engineering around the isotope: closed-loop He-3 recovery, bigger pulse tubes, and modalities (photonics, trapped ions, neutral atoms) that never need millikelvin — the honest bear case is demand routing around the choke, not new supply.

The repricing catalyst is DARPA's Quantum Benchmarking Initiative: 11 Stage-B finalists face Stage-C decisions around late 2026, and any green-lit utility-scale superconducting build is a fleet-scale fridge order whose He-3 line item scales linearly. Nearer in, ASPI's Renergen Phase 1 helium ramp is the cryogen-side proof point.

Be honest about size: global He-3 turnover is tens of millions of dollars and quantum cryogenics a few hundred million — the chokepoint is real while the market is still small. The He-3 line itself is noise inside Linde and Air Products; their helium-4 books are not, since the March 2026 strikes on Qatar removed roughly a third of global helium production and roughly doubled spot prices, making helium pricing power a live street-level catalyst for both. The pure He-3 leverage lives in one small-cap (ASPI), one unsponsored ADR (AIQUY), and two privates the public market cannot buy yet. The listed names are call options on this becoming a procurement crisis — which is how the national-security literature already frames it.